CIK 0001994702 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Kyverna Therapeutics, Inc.
Sign in to watch- Ticker
- KYTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831365441
- Phone
- 5109252492
- Business address
- 5980 HORTON STREET, SUITE 200, EMERYVILLE, CA
- Former names
- Kyverna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-29 | CLARK IAN T Director | Grant or award · Stock Option (right to buy) | +65,351 | 65,351 | ||
| 2025-05-29 | Cohen Fred E Director | Grant or award | +16,634 | 16,634 | ||
| 2025-05-29 | Cohen Fred E Director | Grant or award · Stock Option (right to buy) | +65,351 | 65,351 | ||
| 2025-04-11 | Jones Ryan Alexander Chief Financial Officer | Grant or award | +12,000 | 55,950 | ||
| 2025-04-11 | Walker Karen Marie Chief Technology Officer | Grant or award | +13,000 | 22,636 | ||
| 2025-02-14 | Shaw Christi Director | Grant or award · Stock Option (right to buy) | +38,679 | 38,679 | ||
| 2025-01-22 | GEHCHAN NAJI See Remarks | Grant or award · Stock Option (right to buy) | +425,000 | 425,000 | ||
| 2024-10-21 | Aktar Mert Director | Grant or award · Stock Option (right to buy) | +87,741 | 87,741 | ||
| 2024-09-16 | Biddle Warner Weston Chief Executive Officer | Grant or award · Stock Option (right to buy) | +2,579,259 | 2,579,259 | ||
| 2024-09-16 | Shaw Christi Director | Grant or award · Stock Option (right to buy) | +66,592 | 66,592 | ||
| 2024-06-06 | Walker Karen Marie Chief Technology Officer | Option exercise | +9,636 | $4.42 | $43K | 9,636 |
| 2024-06-06 | Walker Karen Marie Chief Technology Officer | Option exercise · Stock Option (Right to Buy) | −9,636 | 82,648 | ||
| 2024-05-28 | Jones Ryan Alexander Chief Financial Officer | Option exercise | +10,870 | $0.73 | $8K | 36,804 |
| 2024-05-28 | Jones Ryan Alexander Chief Financial Officer | Option exercise | +7,146 | $0.73 | $5K | 43,950 |
| 2024-05-28 | Jones Ryan Alexander Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −10,870 | 0 | ||
| 2024-05-28 | Jones Ryan Alexander Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −7,146 | 2,192 | ||
| 2024-04-11 | Biddle Warner Weston Chief Executive Officer | Grant or award · Stock Option (right to buy) | +332,500 | 332,500 | ||
| 2024-04-11 | Jones Ryan Alexander Chief Financial Officer | Grant or award · Stock Option (right to buy) | +74,000 | 74,000 | ||
| 2024-04-11 | Walker Karen Marie Chief Technology Officer | Grant or award · Stock Option (right to buy) | +80,000 | 80,000 | ||
| 2024-02-12 | Westlake BioPartners Fund I, L.P. 10% owner | Conversion | +3,787,940 | 3,787,940 |
Page 3 of 5 · 91 trades